These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37945692)

  • 1. BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
    Wu Y; Zehnle PMA; Rajak J; Koleci N; Andrieux G; Gallego-Villar L; Aumann K; Boerries M; Niemeyer CM; Flotho C; Bohler S; Erlacher M
    Leukemia; 2024 Jan; 38(1):136-148. PubMed ID: 37945692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
    Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
    Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
    Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.
    Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW
    Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panobinostat inhibits the proliferation of CD34
    Kurata T; Matsuda K; Hirabayashi K; Shigemura T; Sakashita K; Nakahata T; Koike K
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27261. PubMed ID: 30014555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
    Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
    Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
    Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
    Honda Y; Muramatsu H; Nanjo Y; Hirabayashi S; Meguro T; Yoshida N; Kakuda H; Ozono S; Wakamatsu M; Moritake H; Yasui M; Sano H; Manabe A; Sakashita K
    Int J Hematol; 2022 Feb; 115(2):263-268. PubMed ID: 34714526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells.
    Moujalled D; Southon AG; Saleh E; Brinkmann K; Ke F; Iliopoulos M; Cross RS; Jenkins MR; Nhu D; Wang Z; Shi MX; Kluck RM; Lessene G; Grabow S; Bush AI; Strasser A
    Cell Death Differ; 2022 Jul; 29(7):1335-1348. PubMed ID: 35332309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine (Vidaza
    Rubio-San-Simón A; van Eijkelenburg NKA; Hoogendijk R; Hasle H; Niemeyer CM; Dworzak MN; Zecca M; Lopez-Yurda M; Janssen JM; Huitema ADR; van den Heuvel-Eibrink MM; Laille EJ; van Tinteren H; Zwaan CM
    Paediatr Drugs; 2023 Nov; 25(6):719-728. PubMed ID: 37695474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
    Niemeyer CM; Flotho C; Lipka DB; Starý J; Rössig C; Baruchel A; Klingebiel T; Micalizzi C; Michel G; Nysom K; Rives S; Schmugge Liner M; Zecca M; Schönung M; Baumann I; Nöllke P; Benettaib B; Biserna N; Poon J; Simcock M; Patturajan M; Menezes D; Gaudy A; van den Heuvel-Eibrink MM; Locatelli F
    Blood Adv; 2021 Jul; 5(14):2901-2908. PubMed ID: 34297046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of aurora kinases and Bcl-xL induces apoptosis through select BH3-only proteins.
    Li J; Chen CH; O'Neill KL; Fousek-Schuller VJ; Black AR; Black JD; Zhang J; Luo X
    J Biol Chem; 2023 Feb; 299(2):102875. PubMed ID: 36621626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful second allogeneic hematopoietic stem cell transplantation with azacitidine as bridging therapy for relapsed juvenile myelomonocytic leukemia].
    Oshiro T; Hyakuna N; Abe H; Hamada S; Nakanishi K
    Rinsho Ketsueki; 2023; 64(3):187-192. PubMed ID: 37019671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
    Saygin C; Giordano G; Shimamoto K; Eisfelder B; Thomas-Toth A; Venkataraman G; Ananthanarayanan V; Vincent TL; DuVall A; Patel AA; Chen Y; Tan F; Anthony SP; Chen Y; Shen Y; Odenike O; Teachey DT; Kee BL; LaBelle J; Stock W
    Clin Cancer Res; 2023 Aug; 29(16):3151-3161. PubMed ID: 37363966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells.
    Vera MB; Morris-Hanon O; Nogueiras GI; Ripari LB; Esquivel MI; Perez-Castro C; Romorini L; Sevlever GE; Scassa ME; Videla-Richardson GA
    Sci Rep; 2022 Oct; 12(1):17729. PubMed ID: 36273072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A direct comparison of selective BH3-mimetics reveals BCL-X
    Bierbrauer A; Jacob M; Vogler M; Fulda S
    Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.